Validation and reliability of the Dutch version of the EORTC QLQ-NMIBC24 Questionnaire Module for patients with non-muscle-invasive bladder cancer

Theodora M. Ripping1, Ellen Westhoff2, Neil K. Aaronson3, Mieke Van Hemelrijck4, Elke Rammant5, J. Alfred Witjes6, Lambertus. A. Kiemeney2, Katja K. H. Aben1,2 and Alina Vrieling2*

Abstract

Background: The European Organisation for Research and Treatment of Cancer (EORTC) quality of life questionnaire for non-muscle invasive bladder cancer (QLQ-NMIBC24) has been available and applied for some years now, but has yet to undergo a full comprehensive psychometric evaluation. The aim of this study was to investigate the psychometric properties of the Dutch version of the EORTC QLQ-NMIBC24 questionnaire in patients with low, intermediate and high risk NMIBC.

Methods: We included patients newly diagnosed with NMIBC participating in the multicenter, population-based prospective cohort studies UroLife or BlaZIB. Psychometric evaluation included examination of the structural validity, reliability (i.e. internal consistency and test–retest reliability), construct validity (i.e. divergent validity and known-groups validity), responsiveness and interpretability.

Results: A total of 1463 patients who completed the baseline questionnaire of UroLife (n = 541, response rate 50%) or BlaZIB (n = 922, response rate 58%) were included. The percentage of missing responses were low for all non-sex related scales (< 1%) and ranged between 6.9% to 50.0% for sex-related scales. More than 15% of the patients obtained the lowest possible scores on nearly each scale (floor effect). The structural validity was adequate; the confirmatory factor analysis showed satisfactory results and all items of multiple items scales had higher within- than between-scale correlations. Reliability of the questionnaire was adequate for most multiple item scales (Cronbach’s α ≥ 0.70 and intraclass correlation coefficient ≥ 0.70), with exception of the scales ‘malaise’ and ‘bloating and flatulence’. The questionnaire also showed good construct validity; it showed low correlations with the items of the EORTC core questionnaire and was able to measure differences between risk-based subgroups. The responsiveness of the questionnaire was good, but the interpretability, i.e. minimal important change, could not be determined.

Conclusions: This study shows that the measurement properties of the EORTC QLQL-NMIBC24 are good; it has a good structural validity, reliability (i.e. internal consistency and test–retest reliability), construct validity (i.e. divergent validity and known-group validity), and responsiveness. Interpretability could not be assessed. This questionnaire can be used to measure and monitor health-related quality of life of patients with NMIBC.

*Correspondence: Alina.Vrieling@radboudumc.nl
1 Department for Health Evidence, Radboud Institute for Health Sciences, Radboud University Medical Center, PO Box 9101, 6500 HB Nijmegen, The Netherlands
Full list of author information is available at the end of the article
Background
The majority (75%) of new bladder cancer patients are diagnosed with non-muscle invasive bladder cancer (NMIBC) and undergo a transurethral resection (TURBT) [1]. Dependent on the tumour's risk profile, this is followed by a single chemotherapy instillation (low-risk tumours), adjuvant intravesical chemotherapy or Bacillus Calmette Guerin (BCG) for a maximum of 1 year (intermediate-risk tumours), or BCG maintenance for 1–3 years (high-risk tumours) [1]. As both the disease and its treatment can affect functional health and symptom experience, the European Organisation for Research and Treatment of Cancer (EORTC) developed a health-related quality of life (HRQoL) questionnaire specifically for patients with NMIBC, the EORTC Quality of Life Questionnaire (QLQ)-NMIBC24 [2, 3]. This questionnaire module was designed to complement the EORTC core HRQoL questionnaire, the QLQ-C30. The QLQ-NMIBC24 is already partially validated (i.e. content validity) but still needs to undergo psychometric testing in a large international group of patients (phase III validated EORTC module) [4]. To date, three studies have investigated the psychometric properties of the QLQ-NMIBC24 questionnaire showing its psychometric robustness [2, 5, 6]. One study examined and revised the scale structure and evaluated the internal consistency, known group validity, and responsiveness of the questionnaire in a British patient population [2]. The other two studies evaluated the psychometric properties of the Danish and Korean translation of the questionnaire, respectively [5, 6]. However, no full comprehensive evaluation of the psychometric properties of the QLQ-NMIBC24, which is required to judge the appropriateness of the measure, has been performed. Test–retest reliability, interpretability of change scores [7] and the performance of the NMIBC24 has not yet been evaluated in different risk groups of NMIBC patients or among Dutch-speaking patients.

Therefore, the aim of this study was to examine the structural validity, reliability (i.e. internal consistency and test–retest reliability), construct validity (i.e. divergent validity and known group validity), responsiveness and interpretability of the Dutch version of the QLQ-NMIBC24 [3] in patients with low, intermediate and high risk NMIBC.

Methods
Study design and participants
Dutch bladder cancer patients participating in the UroLife (Urothelial cell cancer: Lifestyle, prognosis and quality of Life) or BlaZIB (‘BlaaskankerZorg In Beeld’, clinical trial number: NL8106) studies were included in the current analysis. Both studies are population-based, multicenter prospective cohort studies recruiting newly diagnosed bladder cancer patients based on notifications from the nationwide network and registry of histopathology and cytopathology in the Netherlands (PALGA) and successive registration in the Netherlands Cancer Registry (NCR). The main aim of the UroLife study is to evaluate the association between lifestyle habits and the risk of recurrence and progression and HRQoL of patients with NMIBC. BlaZIB aims to gain insight in bladder cancer care and to identify barriers and modulators for optimal care. More detailed information on these studies can be found elsewhere [8, 9]. For this analysis, patients diagnosed with NMIBC (stage Ta, T1, Tis) between April 1, 2014 and March 18, 2016 were selected from the UroLife study, and patients diagnosed with high-risk NMIBC (stage T1 and Tis) between November 1, 2017 and July 7, 2019 were selected from the BlaZIB study. All patients were Dutch speaking, between 18 and 80 years old, and treated with a transurethral resection. This study was performed in line with the principles of the Declaration of Helsinki. The Committee for Human Research in the region Arnhem-Nijmegen provided ethical approval for the UroLife study (CMO 2013-494) and deemed the BlaZIB study exempt from ethical review under the Medical Research Involving Human Subjects Act (WMO). Both studies were approved by the ethical review board of the NCR. Written informed consent was obtained from all patients participating in UroLife or BlaZIB.

Data collection
Both studies collected self-reported questionnaire data online or on paper 6 weeks after diagnosis (T6wk). The online questionnaires were collected via the data collection tool of the Patient Reported Outcomes Following Initial treatment and Long term Evaluation of Survivorship (PROFILES) registry [10]. Baseline data (T6wk) and follow-up data collected at 3 months (T3mo) and 15 months (T15mo) after diagnosis in the UroLife study, and at 6 months (T6mo) and 12 months (T12mo) after diagnosis in the BlaZIB study were used for the current analysis. The measurement points of UroLife were based on the treatment regimen of patients diagnosed with NMIBC, i.e. shortly after histological confirmation of the tumour (T6wk), at time of cystoscopy to investigate whether the tumour was successfully removed (T3mo), and long-term follow-up (T15mo). For the BlaZIB study,
including also patients with Muscle Invasive Bladder Cancer, different measurement points were selected. Because of the nonconforming measurement points, most analyses were based on UroLife data and only supplemented with BlaZIB data where necessary (i.e. test–retest, interpretability of change scores; see also Fig. 1). The baseline questionnaires assessed demographics, smoking history, and comorbidity. HRQoL was assessed at T6wk and during follow-up using the EORTC-QLQC30 and the QLQ-NMIBC24 questionnaires [2, 11]. Patients who underwent a cystectomy were not or no longer invited to participate in the UroLife study.

In order to assess the test–retest reliability and standard error of measurement (SEM), patients who completed the BlaZIB T12mo questionnaire between March 1st 2019 and December 7th 2019 received an additional questionnaire 2 weeks after the T12mo questionnaire (T12mo+2wk). In total, 134 patients diagnosed with NMIBC completed the T12mo+2wk questionnaire (response rate 86.5%). This questionnaire included the QLQ-NMIBC24 and four additional questions to assess whether the symptoms – in terms of urinary, bowel, sexual and total function – had decreased, remained the same or increased compared to the T12mo questionnaire (three-point Likert scale, see Additional file 1: Appendix A). Patients whose symptoms remained the same were regarded as stable and included in the test–retest analysis.

**Fig. 1** Flowchart BlaZIB and Urolife. NMIBC non-muscle invasive bladder cancer. aPercentage of patients that completed the questionnaire after being invited to fill in the questionnaire. bPercentage of patients that completed the questionnaire after completing the previous questionnaire.
In order to assess the minimal important change (MIC), the follow-up questionnaires of BlaZIB (T6mo, T12mo) contained an anchor question to assess changes over time, i.e. ‘Did your bladder cancer-specific complaints (urinary, bowel, sexual function and overall) change compared to your complaints at diagnosis?’. Patients were asked to score their change on a nine-point Likert scale ranging from 1 (worse than ever) to 9 (no complaints anymore) for urinary, bowel, sexual and total function, separately [12]. We clustered the answers into three categories: importantly deteriorated (1–3), not importantly changed (4–6) and importantly improved (7–9) [13].

HRQoL questionnaires

The EORTC QLQ-C30 is the core HRQoL questionnaire of the EORTC and measures the HRQoL of cancer patients. The questionnaire consists of 30 items organized into a global health status scale, five functioning scales (physical, role, cognitive, emotional, and social), three symptom scales (fatigue, pain, and nausea and vomiting) and six single items (dyspnoea, insomnia, loss of appetite, constipation, diarrhea, and financial impact) [11].

The QLQ-NMIBC24 is an EORTC module for patients diagnosed with NMIBC and should be administered in addition to the core questionnaire (EORTC-QLQ-C30) [4]. The module includes constructs specific to the tumour site and treatment of NMIBC. The QLQ-NMIBC24 consists of 24 items organized into six scales (urinary symptoms, malaise, future worries, bloating and flattulence, sexual functioning, and male sexual problems) and five single items (intravesical treatment issues, sexual intimacy, risk of contaminating partner, sexual enjoyment, female sexual problems) [3].

All items were scored on a four-point Likert scale ranging from 1 (not at all) to 4 (very much), with the exception of the global health status items, which employ a seven-point range from 1 (very poor) to 7 (excellent). Scores of items were summed and linearly transformed to 0–100 scales and missing data were imputed according to the EORTC guideline [14]. Higher scores on functioning scales and global health status represent better functioning, while higher scores on the symptom scales indicate more symptom burden. Higher scores on the scales and items of the QLQ-NMIBC24 should be interpreted as more symptom burden, with exception of the sexual function scale and sexual enjoyment where higher scores represent better functioning.

Statistical analysis

Floor and ceiling effects were examined for each scale at each assessment point. If more than 15% of the patients scored at the lowest or highest end of the scale, the scale was considered to have a floor or ceiling effect, respectively [15]. Multitrait scaling analysis and Confirmatory factor analysis (CFA) were performed to validate the constructs of the QLQ-NMIBC24. Convergent validity was defined as a correlation of 0.40 or greater between an item and its own scale. Discriminant validity was defined as a correlation of less than 0.40 between an item and any other scale [2, 16]. Maximum Likelihood (ML) was used as estimator in the CFA and missing items were imputed using Full Info Max Likelihood (fiml). Model-data-fit of the CFA was assessed with model chi-square, the Comparative Fit Index (CFI), Root Mean Square Error of Approximation (RMSEA) and Standardized Root Mean Square Residual (SRMR). Model chi-square > 0.05, CFI ≥ 0.95, RMSEA < 0.05 and SRMR < 0.05 indicate a good fit, and CFI > 0.90 and both RMSEA and SRMR > 0.05 but < 0.08 indicate an acceptable fit [15, 17]. Internal consistency was assessed with Cronbach’s α. A Cronbach’s α of 0.70 or higher was considered adequate for group level comparisons. Test–retest reliability was assessed based on the questionnaires administered at T12mo and T12mo+2wk using the intraclass correlation coefficient for absolute agreement (ICC; two-way mixed model, single measure) [18]. An ICC value of 0.70 or higher was considered acceptable.

Divergent validity of the QLQ-NMIBC24 was assessed by calculating the Spearman correlation coefficients between the scales of the QLQ-C30 and QLQ-NMIBC24 [19]. Based on previous studies, we expected in general low to moderate correlations (<0.40) between the scales of both questionnaires. Previous studies have shown that malaise was moderately to strongly correlated (>0.40) with all the scales of the QLQ-C30 [2, 6, 16]. The urinary symptom scale has previously also shown to be moderately (0.40–0.69) correlated with role function, cognitive function, social function, fatigue, nausea and vomiting, and pain [2, 6]. At last, future worries was expected to be moderately correlated to the emotional function scale of the QLQ-C30 [2] and fatigue [6].

Known group validity was assessed by comparing patients with low, intermediate and high risk NMIBC using independent t-tests. Patients were divided into risk groups based on the European Association of Urology (EAU) guidelines [1] without taking into account the tumour size (not available) and the recurrent nature of the tumour (only primary tumours included). We hypothesized that patients with high risk NMIBC would have more urinary symptoms, malaise, future worries and intravesical treatment issues at T6wk than patients with low risk NMIBC.

Responsiveness to change was examined using all three questionnaires of the UroLife study (i.e. T6w, T3mo and T15mo) using paired t-tests. We hypothesized that
differences on the scales of the NMIBC24 would only be small between T6wk and T3mo, but that symptoms and complaints decrease from T6wk to T15mo. Effect sizes (ESs) were calculated using Cohen’s d statistic (mean difference divided by pooled standard deviation). These provide a distribution-based estimate of the magnitude of mean differences/changes, where an ES of 0.2 is considered small, 0.5 moderate, and 0.8 large [20].

MIC was assessed using the visual-anchor distribution method of De Vet et al. [13]. This method determines the smallest change in scores of the QLQ-NMIBC24 that are regarded as either improvement or deterioration by taking into account the variability and importance of the scores. To determine the importance of the scores, an external anchor is used. Correlations between the anchor-question and the scales of the QLQ-NMIBC24 were assessed to determine the adequacy of the anchor (r ≥ 0.40) (i.e. does the anchor question measures the same as the change scores?). Then, patients were subdivided into three groups (importantly deteriorated, not importantly changed and importantly improved) using the anchor question and for each group the distribution of the changes scores was plotted. The optimal receiver operating curve (ROC) was considered to be the MIC value.

The CFA was conducted with the software package R using the “lavaan” package [21]. ICCs were calculated in STATA version 16.0 (StataCorp LLC, College Station, Texas, USA) and SEMs were calculated in SAS (SAS Institute, Cary, North Carolina, USA). All other statistical analyses were executed using SPSS version 25 (IBM Corporation, Armonk, New York, USA). P values < 0.05 were considered statistically significant.

Results
Patient characteristics and data quality
Fifty percent of the NMIBC patients invited for UroLife and 58% of the NMIBC patients invited for BlaZIB completed the baseline questionnaire, resulting in a total number of 1463 eligible patients for this study (Fig. 1). Figure 1 presents the number of completed questionnaires and the response rates at follow-up. The majority of the patients were male (81%) (Table 1). Patients participating in UroLife were, on average, younger (66 vs. 72 years), more often female (21% vs. 17%), living together with a partner (85% vs. 77%) and employed (42% vs. 24%) than those participating in BlaZIB.

The percentage of missing responses was low (<1%) for all non-sex related scales at all measurement moments of the UroLife study (Table 2). For the sex-related scales, the percentage of missing responses varied between 6.9 and 12.8%, with exception of female sexual problems (41.4–50.0% missing responses).

At T6wk, only four of the eleven scales had no floor effect (<15%) (Table 2). The highest floor effects were observed for malaise (87.1%) and intravesical treatment issues (74.5%). Over time, the percentage of patients with the lowest possible scores decreased for sexual functioning and male sexual problems but remained stable or increased for all other scales. At T15mo, floor effects were present for all scales. No ceiling effects were observed at any assessment point. The percentage of missing responses was low for all scales, except for female sexual problems (45.7%) (Table 2).

Structural validity
Table 3 shows the results of the multitrait scaling analysis. All items had a within-scale correlation of 0.40 or higher and a correlation of 0.40 or lower with other scales, indicating good convergent and discriminant validity, respectively. The model chi-square significance was <0.0001, CFI was 0.93, RMSEA was 0.06 and SRMR was 0.04 after excluding female sexual function (question answered by N = 21), indicating an acceptable fit. Standardized factor loadings are presented in Table 4.

Reliability
Internal consistency of the scales at all time points was adequate (Cronbach’s α >0.70), with the exception of bloating and flatulence (Cronbach’s α 0.51–0.59) and malaise (Cronbach’s α 0.62–0.67) (Table 3). Test–retest reliability was acceptable for six scales (ICC >0.70) and fair to moderate for three scales (0.38–0.65) (Table 5). Test–retest reliability was the lowest for malaise (0.07).

Construct validity
Correlations between the core questionnaire and the NMIBC-module were low (<0.40) for nearly all scales (Table 6). Only between emotional function (QLQ-C30) and future worries (QLQ-NMIBC24) a moderate, inverse correlation was observed (−0.57). This indicates that the content of the core questionnaire and the NMIBC-specific module do not overlap excessively.

Comparison of patients’ scores at T6wk according to their NMIBC risk subgroups indicated that patients with high-risk NMIBC reported more urinary symptoms (ES = 0.41), future worries (ES = 0.51), problems with sexual intimacy (ES = 0.41) and risk of contaminating partner (ES = 0.72) than patients with low-risk NMIBC (Table 7).

Responsiveness
At T15mo, all QLQ NMIBC24 scores improved compared to T6wk, except for malaise, bloating and flatulence, and male sexual problems (ES < 0.2) (Table 8).
**Table 1** Sociodemographic characteristics of the NMIBC patients

| Patient characteristics | All patients (n = 1463) | BlaZIB High-risk (n = 922) | Urolife All (n = 541) | Low risk (n = 99) | Intermediate risk (n = 250) | High risk (n = 192) |
|-------------------------|-------------------------|---------------------------|----------------------|------------------|-----------------------------|-------------------|
| n (%)                   | N (%)                   | N (%)                     | N (%)                | N (%)            | N (%)                       | N (%)             |
| Age (years), mean (SD)  | 70 (10)                 | 72 (10)                   | 66 (9)               | 65 (10)          | 66 (9)                      | 67 (7)            |
| Gender (% male)         | 1187 (81%)              | 761 (83%)                 | 426 (79%)            | 68 (69%)         | 196 (78%)                   | 162 (84%)         |
| Living situation        |                         |                           |                      |                  |                             |                   |
| With partner            | 1165 (80%)              | 707 (77%)                 | 458 (85%)            | 79 (80%)         | 212 (85%)                   | 167 (87%)         |
| Without partner         | 298 (20%)               | 215 (23%)                 | 83 (15%)             | 20 (20%)         | 38 (15%)                    | 25 (13%)          |
| Employment              |                         |                           |                      |                  |                             |                   |
| Paid job                | 349 (24%)               | 171 (19%)                 | 175 (32%)            | 31 (31%)         | 89 (36%)                    | 55 (29%)          |
| No paid job             | 104 (7%)                | 49 (5%)                   | 55 (10%)             | 13 (13%)         | 25 (10%)                    | 17 (9%)           |
| Retired                 | 1010 (69%)              | 699 (76%)                 | 311 (58%)            | 55 (56%)         | 136 (54%)                   | 120 (62%)         |
| Comorbiditya            |                         |                           |                      |                  |                             |                   |
| 0                       | 299 (20%)               | 212 (23%)                 | 87 (16%)             | 12 (12%)         | 41 (16%)                    | 34 (18%)          |
| 1                       | 406 (28%)               | 270 (29%)                 | 136 (25%)            | 27 (27%)         | 57 (23%)                    | 52 (27%)          |
| ≥ 2                     | 739 (51%)               | 425 (46%)                 | 314 (58%)            | 59 (60%)         | 152 (61%)                   | 103 (54%)         |
| Missing                 | 15 (1%)                 | 15 (2%)                   | 0 (0%)               | 0 (0%)           | 0 (0%)                      | 0 (0%)            |
| Smoking status (at baseline) |                     |                           |                      |                  |                             |                   |
| Never                   | 225 (15%)               | 137 (15%)                 | 88 (16%)             | 19 (19%)         | 40 (16%)                    | 29 (15%)          |
| Former                  | 983 (67%)               | 633 (69%)                 | 350 (65%)            | 63 (64%)         | 155 (62%)                   | 132 (69%)         |
| Current                 | 252 (17%)               | 149 (16%)                 | 103 (19%)            | 17 (17%)         | 55 (22%)                    | 31 (16%)          |
| Missing                 | 3 (0%)                  | 3 (0%)                    | 0 (0%)               | 0 (0%)           | 0 (0%)                      | 0 (0%)            |
| Tumour characteristics  |                         |                           |                      |                  |                             |                   |
| Tumour stage            |                         |                           |                      |                  |                             |                   |
| Ta                      | 403 (28%)               | 0 (0%)                    | 403 (75%)            | 99 (100%)        | 250 (100%)                  | 54 (28%)          |
| T1                      | 907 (62%)               | 786 (85%)                 | 121 (22%)            | 0 (0%)           | 0 (0%)                      | 121 (63%)         |
| Tis                     | 153 (10%)               | 136 (15%)                 | 17 (3%)              | 0 (0%)           | 0 (0%)                      | 17 (9%)           |
| Tumour grade            |                         |                           |                      |                  |                             |                   |
| 1                       | 156 (11%)               | 24 (3%)                   | 132 (24%)            | 99 (100%)        | 29 (12%)                    | 4 (2%)            |
| 2                       | 385 (26%)               | 125 (14%)                 | 260 (48%)            | 0 (0%)           | 221 (88%)                   | 39 (22%)          |
| 3                       | 894 (61%)               | 747 (81%)                 | 147 (57%)            | 0 (0%)           | 0 (0%)                      | 147 (77%)         |
| Missing                 | 28 (2%)                 | 26 (3%)                   | 2 (0%)               | 0 (0%)           | 0 (0%)                      | 2 (1%)            |
| Adjuvant intravesical therapy |                     |                           |                      |                  |                             |                   |
| None                    | 447 (31%)               | 176 (19%)                 | 271 (50%)            | 91 (92%)         | 157 (63%)                   | 23 (12%)          |
| Chemotherapy            | 146 (10%)               | 17 (2%)                   | 129 (24%)            | 7 (7%)           | 82 (33%)                    | 40 (21%)          |
| BCG                     | 808 (55%)               | 690 (75%)                 | 118 (22%)            | 1 (1%)           | 7 (3%)                      | 110 (57%)         |
| BCG + Chemotherapy      | 62 (4%)                 | 39 (4%)                   | 23 (4%)              | 0 (0%)           | 4 (2%)                      | 19 (10%)          |

*BCG Bacillus Calmette-Guérin*  

* Based on an adapted version of the Self-administered Comorbidity Questionnaire [22], including 14 diseases (cardiovascular disease, stroke, high blood pressure, asthma, chronic bronchitis or COPD, diabetes, stomach disease, kidney disease, liver disease, anaemia or other blood disease, thyroid disease, depression, arthrosis, backpain and rheumatism)

**Interpretability**

Based on the correlations between the anchor question and the scales of the questionnaire (ranging between −0.11 and 0.28), the anchor question was deemed inadequate and no MIC values were calculated.

**Discussion**

When evaluating the psychometric properties of the EORTC-QLQ-NMIBC24 in Dutch patients with NMIBC, we observed good structural validity, reliability (i.e. internal consistency and test–retest reliability), construct validity (i.e. divergent validity and known groups validity).
and responsiveness. The number of missing items were low among patients for whom the items were applicable, with exception of female sexual problems. At all measurement points, multiple floor effects were observed and MIC values could not be determined.

Multitrait scaling analysis and Cronbach’s α for internal consistency supported the scale structure of the QLQ-NMIBC24. Only the bloating and flatulence and malaise scales (at follow-up) did not reach the 0.70 cut off for group level use of the items in these scales. Other authors have reported similar results and also found that the bloating and flatulence [2] and especially the malaise scale [2, 5, 6] seems to yield unsatisfactory results. These results suggest that there is heterogeneity of the two items in the malaise scale, i.e. items cannot be grouped into one scale, and a revision of this scale may be needed.

The high number of scales with floor effects we observed at T6wk has also been found by other studies. Park et al. observed floor effects in nine scales and Mogensen et al. found floor effects in 20 out of the 24 items of the questionnaire [5, 6]. Malaise, intravesical treatment issues and bloating and flatulence had the highest percentages of lowest possible scores in all studies (range 43.3% up to 90%) [2, 5, 6]. Floor effects at

Table 2  Missing responses, floor effects and ceiling effects of scales of the EORTC QLQ-NMIBC24 for 541 NMIBC patients participating in UroLife

| Scale                      | T6wk (n = 541) | T3mo (n = 471) | T15mo (n = 423) |
|----------------------------|---------------|---------------|-----------------|
|                            | % Missing     | % Floor       | % Ceiling       | % Missing     | % Floor       | % Ceiling       | % Missing     | % Floor       | % Ceiling       |
| Urinary symptoms           | 0.2           | 9.6           | 0               | 0.4           | 10.4          | 0               | 0.7           | 17.7          | 0               |
| Malaise                    | 0             | 87.1          | 0.6             | 0.2           | 86.8          | 0.2             | 0.7           | 90.8          | 0.2             |
| Future worries             | 0.2           | 14.4          | 1.8             | 0.2           | 18.3          | 0.8             | 0.2           | 24.6          | 0.5             |
| Bloating and flatulence    | 0             | 46.0          | 0.6             | 0.2           | 43.3          | 0.6             | 0.2           | 48.0          | 0.2             |
| Sexual functioning         | 7.8           | 37.3          | 0.6             | 7.4           | 32.3          | 0.4             | 10.6          | 28.4          | 0.5             |
| Male sexual problemsa      | 10.3          | 38.3          | 7.5             | 12.8          | 37.2          | 5.7             | 12.8          | 30.5          | 8.2             |
| Intravesical treatment issuesb | 0.6           | 74.5          | 0.4             | 0.7           | 76.1          | 0.7             | 0.5           | 84.1          | 0.5             |
| Sexual intimacyc           | 7.3           | 62.8          | 0.9             | 6.9           | 70.1          | 1.3             | 7.4           | 70.5          | 0.5             |
| Risk of contaminating partner | 7.7           | 52.6          | 3.4             | 7.8           | 61.0          | 1.3             | 7.4           | 71.1          | 2.1             |
| Sexual enjoyment           | 9.0           | 17.5          | 3.8             | 9.1           | 14.3          | 3.0             | 8.4           | 20.5          | 3.2             |
| Female sexual problemsd    | 45.7          | 14.3          | 0               | 50.0          | 36.7          | 6.7             | 41.4          | 44.8          | 0               |

a For 426 (T6wk)/368 (T3mo)/328 (T15mo) men
b For 502 (T6wk)/451 (T3mo)/402 (T15mo) men and women indicating this item was applicable to them
c For 234 (T6wk)/231 (T3mo)/219 (T15mo) men and women indicating to be sexually active
d For 35 (T6wk)/30 (T3mo)/29 (T15mo) women indicating to be sexually active

Table 3  Item convergent and discriminant correlations by scale within the EORTC QLQ-NMIBC24 at each follow-up time point for 541 NMIBC patients participating in UroLife (multitrait scaling analysis and internal consistency)

| Scale                        | T6wk (n = 541) | T3mo (n = 471) | T15mo (n = 423) |
|------------------------------|---------------|---------------|-----------------|
|                              | Cona           | Disb          | αc              | Cona           | Disb          | αc              | Cona           | Disb          | αc              |
| Urinary symptoms             | 0.53–0.82     | −0.21 to 0.26 | 0.85            | 0.51–0.82     | −0.18 to 0.31 | 0.86            | 0.45–0.84     | −0.11 to 0.27 | 0.82            |
| Malaise                      | 0.57–0.97     | −0.02 to 0.26 | 0.72            | 0.61–0.97     | −0.15 to 0.29 | 0.67            | 0.61–0.98     | −0.05 to 0.20 | 0.62            |
| Future worries               | 0.82–0.89     | −0.06 to 0.25 | 0.90            | 0.83–0.87     | −0.07 to 0.26 | 0.89            | 0.83–0.88     | 0.00–0.26     | 0.90            |
| Bloating and flatulence      | 0.74–0.89     | −0.07 to 0.22 | 0.59            | 0.71–0.89     | −0.05 to 0.27 | 0.57            | 0.66–0.90     | −0.13 to 0.23 | 0.51            |
| Sexual functioning           | 0.91–0.94     | −0.21 to (−0.02) | 0.83          | 0.92–0.95     | −0.28 to (−0.05) | 0.86         | 0.91–0.95     | −0.19 to (−0.04) | 0.85         |
| Male sexual problemsa        | 0.83–0.92     | −0.21 to 0.25 | 0.77            | 0.88–0.91     | −0.28 to 0.31 | 0.77            | 0.85–0.91     | −0.19 to 0.27 | 0.74            |

Con convergent validity, dis discriminant validity
a Range of item-scale correlations corrected for overlap
b Range of correlations between an item and all other scales
c Cronbach’s alpha
baseline may impose a problem as further decreases in symptoms and function over time, as is the case in our study, cannot be measured. Reviewing the relevance of scales with high floor effects at baseline might improve the usefulness of this questionnaire.

The low correlations between the scales of the QLQ-C30 and the QLQ-NMIBC24 questionnaires indicate good discriminant validity and added value of the QLQ-NMIBC24 to the core questionnaire. We could not confirm the moderate correlation (> 0.40) between malaise and urinary symptoms of the QLQ-NMIBC24 and the scales of the QLQ-C30 as observed in previous studies, but did confirm the moderate correlation between future worries and emotional function [2, 6].

We found that the QLQ-NMIBC24 is able to discriminate between subgroups (i.e., NMIBC risk profile) and to measure change over time. However, the difference found for malaise by NMIBC risk profile was small and non-significant. Other studies have found significant differences in most scales according to physical function (> 90 vs < 90) [2] and Karnofsky performance status [6]. For gender comparisons, only differences in sexual function and sexual enjoyment were observed [2;6]. All studies were able to detect changes in score over time [2, 6].

For the test–retest reliability and interpretability, we used an anchor-question and measurement scale to determine changes in patient’s health over the course of time in line with previous recommendations [12]. However, it might not be suitable to assess changes in malaise (ICC of 0.07) as other, non-bladder cancer related, health issues may affect malaise as well. Furthermore, both malaise, as a consequence of treatment, and intravesical treatment issues are highly dependent on the timing of the questionnaire in the treatment process, which might also explain the rather low test–retest reliability for these scales. In addition, we were not able to calculate

Table 4 Standardised factor loadings for the EORTC QLQ-NMIBC24 for 541 NMIBC patients participating in UroLife (confirmatory factor analysis)

| Scales and items           | Item # | Item topic                                                                 | Standardized factor loadings^b |
|---------------------------|--------|-----------------------------------------------------------------------------|--------------------------------|
| Urinary symptom           | Item 31| Have you had to urinate frequently during the day?                          | 0.682                          |
|                           | Item 32| Have you had to urinate frequently at night?                                | 0.622                          |
|                           | Item 33| When you felt the urge to pass urine, did you have to hurry to get to the toilet? | 0.768                          |
|                           | Item 34| Was it difficult for you to get enough sleep, because you needed to get up frequently at night to urinate? | 0.593                          |
|                           | Item 35| Have you had difficulty going out of the house, because you needed to be close to a toilet? | 0.586                          |
|                           | Item 36| Have you had any unintentional release (leakage) of urine?                  | 0.334                          |
|                           | Item 37| Have you had pain or a burning feeling when urinating?                      | 0.497                          |
| Malaise                   | Item 38| Did you have a fever?                                                       | 0.159                          |
|                           | Item 39| Did you feel ill or unwell?                                                  | 0.591                          |
| Future worries            | Item 40| Did you worry about having repeated bladder treatments (cystoscopies or instillations)? | 0.618                          |
|                           | Item 41| Were you worried about your health in the future?                           | 0.692                          |
|                           | Item 42| Did you worry about the results of examinations and tests?                  | 0.700                          |
|                           | Item 43| Did you worry about possible future treatments?                             | 0.736                          |
| Bloating and flatulence   | Item 44| Did you have a bloated feeling in your abdomen?                             | 0.696                          |
|                           | Item 45| Have you had flatulence or gas?                                              | 0.339                          |
| Sexual functioning        | Item 46| Have you had a bloated feeling in your abdomen?                             |                                |
|                           | Item 47| To what extent were you interested in sex?                                  | 0.700                          |
|                           | Item 48| To what extent were you sexually active (with or without sexual intercourse)?| 0.542                          |
| Male sexual problems      | Item 49| For men only: Do you have difficulty gaining or maintaining an erection?    | 0.870                          |
|                           | Item 50| For men only: Did you have ejaculation problems (e.g. dry ejaculation)?      | 0.827                          |
| Intravesical treatment issues | Item 51| Did you have trouble arranging your life around the repeated bladder treatment appointments (cystoscopies or instillations)? | 0.564                          |
| Sexual intimacy           | Item 52| Have you felt uncomfortable about being sexually intimate?                  | 0.690                          |
| Risk of contaminating partner | Item 53| Have you worried that you may contaminate your partner during sexual contact with the bladder treatment you have been receiving? | 0.821                          |
| Sexual enjoyment          | Item 54| To what extent was sex enjoyable for you?                                   | 0.941                          |
| Female sexual problemsa   | Item 55| For women only: Did you have a dry vagina or other problems during intercourse? |                                |

^a This scale was excluded from the confirmatory factor analysis
^b All p values were < 0.0001
MIC values as the correlations between the scores on the anchor-question and change scores were too low. Other factors, such as the different modes of administration in the test–retest analysis (online vs. paper), may have also contributed to these findings. Future research will be necessary to determine MIC values for the NMIBC24.

A limitation of this study is the response rate for both questionnaires, i.e. 50% and 58% for UroLife and BlaZIB, respectively. Although our response rates are as expected for Dutch patients with NMIBC, selective non-response may affect the generalizability of the scores to the entire Dutch patient population with NMIBC. We do, however, not expect selective non-response as participants of the UroLife study were comparable with respect to age, gender and tumour stage to the non-responders (data not shown). Furthermore, selective loss to follow-up might have affected some of our results concerning comparison of outcomes over time (i.e. responsiveness), although analyses based on patients who participated in all three UroLife questionnaires (T6wk, T6mo and T15mo) showed similar results (data not shown). At last, the sparse number of sexual active women in our study (n = 35 at T6wk; n = 0 test–retest analysis) limited the examination of the item female sexual problems; we omitted this item from the CFA and could not assess the ICC. Previous studies investigating the psychometric properties of the QLQ-NMIBC24 have also dealt with a low number of female sexual active participants [2, 5, 6].

### Table 5

Intraclass correlation coefficient of the QLQ-NMIBC24 subscales for 134 NMIBC patients participating in the test–retest analysis of BlaZIB

| Scale                        | Assessment of stability | Number of stable patients | ICC      | (95% CI)             | SEMa |
|------------------------------|-------------------------|---------------------------|----------|----------------------|------|
| Urinary symptoms             | Urinary function        | 80                        | 0.70     | (0.57–0.80)          | 10.0 |
| Malaise                      | Total function          | 78                        | 0.07     | (−0.15 to 0.29)      | 12.9 |
| Future worries               | Total function          | 60                        | 0.78     | (0.66–0.86)          | 8.4  |
| Bloating and flatulence      | Bowel function          | 56                        | 0.65     | (0.46–0.78)          | 12.4 |
| Sexual functioning           | Sexual function         | 58                        | 0.82     | (0.72–0.89)          | 8.9  |
| Male sexual problems         | Sexual function         | 49                        | 0.74     | (0.57–0.84)          | 18.3 |
| Intravesical treatment issues| Total function          | 76                        | 0.38     | (0.17–0.56)          | 11.8 |
| Sexual intimacy              | Sexual function         | 22                        | 0.73     | (0.46–0.88)          | 11.4 |
| Risk of contaminating partner| Sexual function         | 20                        | 0.40     | (−0.04 to 0.71)      | 15.2 |
| Sexual enjoyment             | Sexual function         | 20                        | 0.71     | (0.40–0.87)          | 14.9 |
| Female sexual problems       | Sexual function         | 0                         |          |                      |      |

**Note:**
- ICC: intraclass correlation coefficient, CI: confidence interval, SEM: standard error of measure
- Using the Restricted Maximum Likelihood (REML) approach
- Patients who (self-reported) remained the same with respect to the specific assessment of stability (i.e. urinary, bowel, sexual or total function) between the T12mo and T12mo + 2wk questionnaire

### Table 6

Spearman correlations between scales in the QLQ-C30 and QLQ-NMIBC24 for 541 NMIBC patients participating in UroLife (divergent validity)

| QLQ-C30 scales | QLQ-NMIBC24 scales |
|----------------|--------------------|
|                | Urinary symptoms   | Malaise              | Future worries | Bloating and flatulence | Sexual function | Male sexual problems |
| Physical function (+) | −0.23     | −0.16    | −0.11       | −0.13       | 0.24         | −0.18       |
| Role function (+)   | −0.33     | −0.27    | −0.22       | −0.23       | 0.14         | −0.14       |
| Emotional function (+) | −0.25     | −0.24    | −0.57       | −0.26       | 0.10         | −0.12       |
| Cognitive function (+) | −0.15     | −0.20    | −0.21       | −0.24       | 0.07         | −0.17       |
| Social function (+)  | −0.31     | −0.26    | −0.32       | −0.25       | 0.12         | −0.14       |
| Global Quality of Life (+) | −0.38     | −0.33    | −0.37       | −0.25       | 0.16         | −0.16       |
| Pain (−)            | 0.35      | 0.27     | 0.31        | 0.25        | −0.13        | 0.15        |
| Fatigue (−)          | 0.26      | 0.28     | 0.27        | 0.26        | −0.15        | 0.12        |
| Nausea and vomiting (−) | 0.14      | 0.36     | 0.10        | 0.17        | −0.03        | 0.03        |

**Note:** The signs (−) and (+) indicate whether higher scores on this scale are worse or better, respectively

- a Using the Restricted Maximum Likelihood (REML) approach
- b Patients who (self-reported) remained the same with respect to the specific assessment of stability (i.e. urinary, bowel, sexual or total function) between the T12mo and T12mo + 2wk questionnaire

---

**The signs (−) and (+) indicate whether higher scores on this scale are worse or better, respectively**
and often lower than is considered adequate according to the COSMIN study design checklist for patient-reported outcome measures [7]. As a consequence, it is hard to draw solid conclusions about the single item female sexual problems.

### Conclusions

The QLQ-NMIBC24 questionnaire has in general a good structural validity, reliability, construct validity and responsiveness. The reliability of the scales malaise and bloating and flatulence is, however, suboptimal. Relevant change scores for this questionnaire could not be defined.

#### Table 7
Mean scores (± SD) of EORTC QLQ-NMIBC24 subscales at 6 weeks after diagnosis for 541 NMIBC patients participating in UroLife by risk category (known group validity)

| Patient score, mean (SD) | Low risk (N = 99) | Intermediate risk (N = 250) | High risk (N = 192) | Effect size<sup>a</sup> | Intermediate vs. low | High vs. low |
|--------------------------|-------------------|-----------------------------|---------------------|------------------------|---------------------|--------------|
| Urinary symptoms (-)<sup>d</sup> | 24.5 (20.8) | 26.3 (20.1) | 33.1 (21.3) | 0.09 | 0.41<sup>c</sup> |
| Malaise (-)<sup>d</sup> | 2.4 (10.8) | 3.7 (13.7) | 4.3 (10.4) | 0.11 | 0.18 |
| Future worries (-)<sup>d</sup> | 28.4 (20.8) | 30.6 (24.1) | 40.1 (24.5) | 0.10 | 0.51<sup>c</sup> |
| Bloating and flatulence (-)<sup>d</sup> | 21.6 (23.2) | 15.4 (20.5) | 17.8 (20.8) | −0.28<sup>b</sup> | −0.17 |
| Sexual functioning (+)<sup>d</sup> | 23.3 (22.3) | 21.5 (22.9) | 21.7 (22.4) | −0.08 | −0.07 |
| Male sexual problems (-)<sup>d</sup> | 30.9 (30.1) | 26.5 (33.1) | 29.1 (33.1) | −0.14 | −0.07 |
| Intravesical treatment issues (-)<sup>d</sup> | 9.9 (17.6) | 8.0 (17.9) | 12.7 (20.4) | −0.11 | 0.15 |
| Sexual intimacy (-)<sup>d</sup> | 9.2 (19.3) | 12.1 (21.7) | 18.2 (24.2) | 0.14 | 0.41<sup>b</sup> |
| Risk of contaminating partner (-)<sup>d</sup> | 9.7 (21.7) | 15.5 (22.8) | 29.1 (31.3) | 0.26 | 0.72<sup>c</sup> |
| Sexual enjoyment (+)<sup>d</sup> | 47.2 (28.2) | 44.3 (29.3) | 44.4 (31.2) | −0.10 | −0.09 |
| Female sexual problems (-)<sup>d</sup> | 37.5 (33.0) | 33.3 (19.2) | 27.8 (25.1) | −0.16 | 0.33 |

<sup>a</sup> Effect size of 0.2 is considered small, 0.5 moderate, and 0.8 large
<sup>b</sup> p ≤ 0.05
<sup>c</sup> p ≤ 0.01
<sup>d</sup> The signs (–) and (+) indicate whether higher scores on this scale are worse or better, respectively

#### Table 8
Unadjusted mean scores (± SD) of EORTC QLQ-NMIBC24 subscales for 541 NMIBC patients participating in UroLife at three time points after diagnosis and mean differences at 3 months (T3mo) and 15 months (T15mo) compared to 6 weeks (T6wk) after diagnosis (responsiveness)

| Patient score, mean (SD) | T6wk (N = 541) | T3mo (N = 471) | T15mo (N = 423) | Effect size<sup>a</sup> | T3mo vs. T6wk | T15mo vs. T6wk |
|--------------------------|---------------|---------------|---------------|------------------------|--------------|--------------|
| Urinary symptoms (-)<sup>d</sup> | 28.4 (21.0) | 22.3 (19.3) | 17.8 (16.4) | −0.27<sup>d</sup> | −0.53<sup>d</sup> |
| Malaise (-)<sup>d</sup> | 3.7 (12.1) | 3.4 (10.5) | 2.5 (9.5) | −0.02 | −0.08 |
| Future worries (-)<sup>d</sup> | 33.6 (24.1) | 29.5 (22.6) | 24.7 (21.4) | −0.17<sup>d</sup> | −0.38<sup>d</sup> |
| Bloating and flatulence (-)<sup>d</sup> | 17.4 (21.2) | 17.1 (20.4) | 14.4 (18.0) | 0.00 | −0.14<sup>c</sup> |
| Sexual functioning (+)<sup>d</sup> | 21.9 (22.6) | 24.4 (22.2) | 27.1 (23.2) | 0.09<sup>d</sup> | 0.23<sup>d</sup> |
| Male sexual problems (-)<sup>d</sup> | 28.1 (32.6) | 27.5 (31.2) | 33.3 (33.0) | −0.01 | 0.12<sup>b</sup> |
| Intravesical treatment issues (-)<sup>d</sup> | 10.0 (18.8) | 9.5 (18.7) | 6.2 (15.7) | 0.02 | −0.23<sup>d</sup> |
| Sexual intimacy (-)<sup>d</sup> | 13.8 (22.4) | 10.4 (20.0) | 10.1 (19.2) | −0.20<sup>d</sup> | −0.29<sup>c</sup> |
| Risk of contaminating partner (-)<sup>d</sup> | 19.3 (27.0) | 14.3 (22.7) | 10.0 (21.5) | −0.20<sup>d</sup> | −0.46<sup>d</sup> |
| Sexual enjoyment (+)<sup>d</sup> | 45.0 (29.7) | 42.9 (26.5) | 41.9 (29.1) | −0.12 | −0.20<sup>b</sup> |
| Female sexual problems (-)<sup>d</sup> | 33.3 (25.8) | 18.8 (36.5) | 12.7 (24.7) | −0.34 | −1.16<sup>b</sup> |

<sup>a</sup> Effect size was calculated using Cohen’s d statistic (mean difference divided by pooled standard deviation) and 0.2 is considered small, 0.5 moderate, and 0.8 large
<sup>b</sup> p ≤ 0.05
<sup>c</sup> p ≤ 0.01
<sup>d</sup> p ≤ 0.001
<sup>e</sup> The signs (–) and (+) indicate whether higher scores on this scale are worse or better, respectively
due to the low anchor question and change scores.

Abbreviations

BCG: Bacillus Calmette Guerin, BlaZIB: ‘BlaaskankerZorg In Beeld’ (EN: Insight into bladder cancer care), CFA: Confirmatory factor analysis; CFI: Comparative Fit Index; CMO: Committee for Human Research; COSMIN: COnsensus-based Standards for the selection of health Measurement INstruments; EAU: European Association of Urology; EORTC: European Organisation for Research and Treatment of Cancer; EORTC: QLQ-C30 European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30; EsS: Effect sizes; fiml: Full Info Max Likelihood; HRQol: Health-Related Quality of Life; ICC: intra-class correlation; MIC: minimal important change; ML: Maximum Likelihood; Mo: Month; NCR: Netherlands Cancer Registry; NMIBC: Non-Muscle Invasive Bladder Cancer; PALGA: nationwide network and registry of histopathology and cytopathology in the Netherlands; PROFILES: Patient Reported Outcomes Following Initial treatment and Long term Evaluation of Survivors; QLQ-NMIBC24: Quality of life Questionnaire for Non-Muscle Invasive Bladder Cancer; RMSEA: Root Mean Square Error of Approximation; ROC: Receiver Operating Curve; SRMR: Standardized Root Mean Square Residual, UroLife: Urinary cell cancer. Lifestyle, prognosis and quality of Life; SEM: standard error of measurement; TURBT: Transurethral Resection; WMO: the (Dutch) Medical Research Involving Human Subjects Act; Wk: week.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s41687-021-00372-4.

Acknowledgements

We are grateful to all the patients who participated in UroLife and BlaZIB and thank all hospitals who were involved in the recruitment of patients. The authors also thank the research assistants for the HRQL data collection and the registration team of the Netherlands Comprehensive Cancer Organisation (IKNL) for the collection of data for the Netherlands Cancer Registry. We would like to thank the following hospitals for their involvement in recruitment for the UroLife study: Amphia Ziekenhuis, Breda/DenBosch (Drs. D.K. van der Schouw); Ziekenhuis Beuningen, Uden (Drs. A.O.H.J. Niemier); Canisius-Wilhelmina Ziekenhuis, Nijmegen (Dr. D.M. Somford); Catharina Ziekenhuis, Eindhoven (Dr. E.L. Koldeuwijn); Deventer Ziekenhuis, Deventer (Drs. P.L.M. van den Tillaar); Elkerliek Ziekenhuizen, Helmond (Drs. W.E. Stapper, Dr. P.J. van Hest); Gelre Ziekenhuizen, Apeldoorn/Zutphen (Drs. D.M. Bochove-Overgaauw); Isala Klinieken, Zwolle (Dr. E. te Slaa); Jeroen Bosch Ziekenhuis, ’s-Hertogenbosch (Dr. J.B. Oddens); Dr. S. van der Meel), Meander Medisch Centrum, Arnhem (Drs. F.S. van Rey); Medisch Spectrum Twente, Enschede (Dr. M. Asselman); Provinciale Klinieken, Zwolle (Dr. E. te Slaa); Jeroen Bosch Ziekenhuis, ’s-Hertogenbosch; Rijnstate, Arnhem/Velp/Zevenaar (Drs. C.J. Wijburg); Maxima Medisch Centrum, Veldhoven/Eindhoven (Dr. L.M.C.L. Fossion); Maasziekenhuis Pantein, Boxmeer (Drs. E. van Booven); Radboudumc, Nijmegen (Prof. Dr. J.A. Witjes); Rijnstate, Arnhem/Velp/Zevenaar (Drs. C.J. Wijburg); Slingeland Ziekenhuizen, Doetinchem (A.D.H. Goebos); St. Anna Ziekenhuis, Geldrop (Drs. A. Sonneveld); Elisabeth-TweeSteden Ziekenhuis, Tilburg/Waalwijk (Dr. P.M.J. Klu); St. Jansdal Ziekenhuis, Harderwijk (Drs. W.J. Kniestdett); VeeCuri, Venlo (Drs. G. Yurdakul, Dr. A.H.P. Meier); Ziekenhuis Gelderse Vallei, Ede (Drs. M.D.H. Kortleve); Ziekenhuisgroep Twente, Almelo/Hengelo (Dr. E.B. Cornel). In addition, we thank Ms. Monique Eigenberger for her assistance in data collection. We would like to thank the following members of the BlaZIB study group for their contribution to the BlaZIB study: Dr. J. Boormans (Erasmus Medical Center), Dr. A.G. van der Heijden (Radboudumc), S. Heldere (Patient association Leven met blaas- of nierkanker), L.M.C. van Hoogstraten (IKNL), Dr. M.C.M. Hulshof (Amsterdam University Medical Centers, location AMC), Dr. C.A. Goossens (Alrijne hospital), Dr. G.J.H. van Leenders (Erasmus Medical Center), Dr. A.M. van Leeuwen (University Medical Center Groningen), Dr. R.F. Meijer (University Medical Center Utrecht), Prof. Dr. R.J.A. van Moorselaar (Amsterdam University Medical Centers, location VUMc), Dr. S. Mulder (Radboudumc), Dr. R.I. Nooter (St. Franciscus ziekenhuis), Dr. J.L. Noteboom (University Medical Center Utrecht), Dr. J.R. Oddens (Amsterdam University Medical Centers, location AMC), Dr. T. de Reijke (Amsterdam University Medical Centers, location AMC), Dr. B.W.G. van Rhijn (Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital), Dr. J.G.H. van Roermund (Maastricht University Medical Center), Dr. T.J. Smidte (Jeroen Bosch ziekenhuis), A. Vanderbosch (Patient association Leven met blaas- of nierkanker), Dr. B.P. Wijman (Elisabeth-TweeSteden ziekenhuis).

Authors’ contributions

All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by Theodora M. Ripping, Ellen Westhoff, Katja K.H. Aben and Alina Vrielings. The first draft of the manuscript was written by Theodora M. Ripping, Ellen Westhoff and Alina Vrielings and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Funding

The UroLife study is funded by Alpe d’Huez/Dutch Cancer Society (KUN 2013-5926) and Dutch Cancer Society (Project No. 11179). The BlaZIB study is funded by the Dutch Cancer Society (IKNL 2015-7914). The funding agencies had no role in the design, data collection, analysis, and interpretation of the results of this study.

Availability of data and materials

The data are currently not publicly available.

Declarations

Ethics approval and consent to participate

The UroLife study obtained ethical approval of the Committee for Human Research in the region Arnhem-Nijmegen (CM) 2013-494). For the BlaZIB study, the need for ethical approval was waived by the Committee for Human Research in the region Arnhem-Nijmegen. Informed consent was obtained from all individual participants included in the study.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

1. Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands.
2. Department for Health Evidence, Radboud Institute for Health Sciences, Radboud University Medical Centers, location AMC, Netherlands.
3. Division of Biological Science, Radboud Institute for Health Sciences, Radboud University Medical Centers, location AMC, Netherlands.
4. Faculty of Life Sciences and Medicine, Translational Oncology and Urology Research (TOUR), King’s College London, London, UK.
5. Department of Human Structure and Repair, Ghent University, Ghent, Belgium.
6. Department of Urology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.

Received: 15 March 2021 Accepted: 9 September 2021

References

1. Babjuk M, Burger M, Comperat EM, Gontero P, Mostafid AH, Palou J, van Rhijn BWG, Roupret M, Shariat SF, Sylvester R, Zigeuner R, Capoun O, Cohen D, Escrig A, Hernandez V, Peyronnet B, Seisen T, Soukup V (2019) European Association of Urology Guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ)—2019 update. Eur Urol 76(5):639–657.
2. Blazevic JM, Hall E, Aaronson N, Lloyd L, Waters R, Kelly JD, Fayers P (2014) Validation and reliability testing of the EORTC QLQ-NMIBC24.
questionnaire module to assess patient-reported outcomes in non-muscle-invasive bladder cancer. Eur Urol 66(6):1148–1156

3. EORTC Quality of Life Study Group (1994) EORTC QLQ - NMIBC24. EORTC. https://qol.eortc.org/questionnaire/qlq-nmibc24/. Accessed 7 June 2021

4. Johnson C, Aaronson NK, Blazeby JM, Bottemley A, Fayers P, Koller M, Kulis D, Ramage J, Sprangers M, Velikova G, Young T (2011) Guidelines for developing questionnaire modules. Available via EORTC. https://qol.eortc.org/Upload/sites/2/2018/02/guidelines_for_developing_questionnaire_final.pdf. Accessed at 7 June 2021

5. Mogensen K, Christensen KB, Vrang ML, Hermann GG (2016) Hospitalization for transurethral bladder resection reduces quality of life in Danish patients with non-muscle-invasive bladder tumour. Scand J Urol 50(3):170–174

6. Park J, Shin DW, Kim TH, Jung SI, Nam JK, Park SC, Hong S, Jung JJ, Kim HW, Kim WT (2017) Development and Validation of the Korean Version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients with Non-muscle Invasive Bladder Cancer—EORTC QLQ-NMIBC24. Cancer Res Treat 50(1):40–49

7. Mokkink LB, Prinsen CAC, Patrick DL, Alonso J, Bouter LM, de Vet HCW, Terwee CB (2019) COSMIN Study Design checklist for Patient-reported outcome measurement instruments. Amsterdam University Medical Centers, Location VUMc, Amsterdam, pp 1–32

8. de Goeij L, Westhoff E, Witjes JA, Aben KK, Kampman E, Kiemeney LA, Vrieling A (2019) The UroLife study: protocol for a Dutch prospective cohort on lifestyle habits in relation to non-muscle-invasive bladder cancer prognosis and health-related quality of life. BMJ Open 9(10):e030396

9. Ripping TM, Kiemeney LA, van Hoogstraten LMC, Witjes JA, Aben KKH (2020) Insight into bladder cancer care: study protocol of a large nationwide prospective cohort study (BlazIB). BMC Cancer 20(1):455

10. van de Poll-Franse LV, Horevoorts N, van Eenbergen M, Denollet J, Roukema JA, Aaronson NK, Vingerhoets A, Coebergh JW, de Vries J, Essink-Bot ML, Mols F (2011) The Patient Reported Outcomes Following Initial treatment and Long term Evaluation of Survivorship registry: scope, rationale and design of an infrastructure for the study of physical and psychosocial outcomes in cancer survivorship cohorts. Eur J Cancer 47(14):2188–2194

11. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cuil A, Duez NJ, Filiberti A, Flechtmann H, Fleishman SB, de Haes JCJM, Kaasa S, Klee MC, Osoba D, Razavi D, Rofe PB, Schraub S, Sneeuw KCA, Sullivan M, Takeda F (1993) The European Organisation for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials on oncology. J Natl Cancer Inst 85:365–376

12. Kamper S, Maher C, Mackay G (2009) Global rating of change scales: a review of strengths and weaknesses and considerations for design. J Manual Manipulative Ther 17:163–170

13. de Vet HC, Ostelo RW, Terwee CB, van der Roer N, Knol DL, Beckerman H, Boers M, Bouter LM (2007) Minimally important change determined by a visual method integrating an anchor-based and a distribution-based approach. Qual Life Res 16(1):131–142

14. Fayers P, Aaronson N, Bjordal K, Groenvold M, Curran D, Bottomley A (2001) EORTC QLQ-C30 scoring manual, 3rd edn. EORTC, Brussel

15. McHorney CA, Tarlov AR (1995) Individual-patient monitoring in clinical practice: are available health status surveys adequate? Qual Life Res 4(4):293–307

16. Schober P, Boer C, Schwarte LA (2018) Correlation coefficients: appropriate use and interpretation. Anesth Analg 126(5):1763–1768. https://doi.org/10.1213/ANE.0000000000002864

17. Hu LT, Bentler PM (1999) Cutoff criteria for fit indexes in covariance structure analysis: conventional criteria versus new alternatives. Struct Equ Model Multidiscip J 6(1):1–55

18. Shrout PE, Fleiss JL (1979) Intraclass correlations: uses in assessing rater reliability. Psychol Bull 86(2):420–428

19. Mukaka MM (2012) Statistics corner: a guide to appropriate use of correlation coefficient in medical research. Malawi Med J 24(3):69–71

20. Cohen J (1977) Statistical power analysis for the behavioural sciences. Academic Press, New York

21. Rosseel Y (2012) lavaan: an R package for structural equation modeling. J Stat Softw 48(2):1–36

22. Sangha O, Stucki G, Liang MH, Fossel AH, Katz JN (2003) The Self-Administered Comorbidity Questionnaire: a new method to assess comorbidity for clinical and health services research. Arthritis Rheum 49(2):156–163. https://doi.org/10.1002/art.10993

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.